Abstract The appropriate immunosuppressive regimen in kidney transplant recipients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2/COVID-19) infection remains unclear. The impact of direct virus injury complicated by dysregulated hyperimmune response with overwhelming release of various cytokines in COVID-19 infected subjects contributes to the complexity of management. The largest concern of the practicing clinicians at current time is how to tailor maintenance immune-modulating therapy during active viral infection and the efficacy of the soon-to-be upcoming immunization for COVID-19. This targeted review aims to cover most of the current evidence on the effect of key maintenance immunosuppressive agents in COVID-19 infection and proposes a line of management to specific scenarios on this very rapidly evolving subject.
【저자키워드】 COVID-19; kidney transplant; bamlanivimab; immunosuppression; ivermectin; CNI., 【초록키워드】 COVID-19, Efficacy, therapy, Infection, cytokine, virus, immunization, COVID-19 infection, management, kidney transplant recipient, Coronavirus-2, Evidence, Injury, immunosuppressive, regimen, acute respiratory syndrome, clinician, subject, active viral infection, contribute, dysregulated, immunosuppressive agent, hyperimmune response, 【제목키워드】 Infection, kidney transplant recipient, with COVID-19,